Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
ASX:BNO

Bionomics (BNO) Stock Price, News & Analysis

→ Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad)
Free BNO Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
386,458 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNO Stock News Headlines

December 18, 2023 | investing.com
Bionomics ADR (BNOX) Earnings Dates & Reports
July 3, 2023 | finance.yahoo.com
Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth
March 9, 2023 | finanznachrichten.de
Bionomics Ltd: Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)
February 24, 2023 | finance.yahoo.com
Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)
February 23, 2023 | finanznachrichten.de
Bionomics Ltd: Bionomics' Half-Year Report
February 5, 2023 | finance.yahoo.com
Will Bionomics (ASX:BNO) Spend Its Cash Wisely?
December 27, 2022 | finance.yahoo.com
All Focus Shifts To Bionomics' PTSD Study After Anxiety Trial Disappoints
December 18, 2022 | finance.yahoo.com
Bionomics Reports Topline Results in PREVAIL Phase 2 Study of BNC210 in Social Anxiety Disorder
November 16, 2022 | finance.yahoo.com
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
October 25, 2022 | finance.yahoo.com
Quarterly Activities Report for September 2022
October 18, 2022 | finance.yahoo.com
Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million
October 7, 2022 | finance.yahoo.com
Bionomics (ASX:BNO) adds AU$20m to market cap in the past 7 days, though investors from five years ago are still down 84%
October 4, 2022 | finance.yahoo.com
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
September 24, 2022 | reuters.com
BNO.AX - Bionomics Ltd | Stock Price & Latest News | Reuters
August 30, 2022 | finance.yahoo.com
Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect?
August 27, 2022 | finance.yahoo.com
We're Keeping An Eye On Bionomics' (ASX:BNO) Cash Burn Rate
July 8, 2022 | finance.yahoo.com
Bionomics to Participate in William Blair’s Biotech Focus Conference 2022
June 13, 2022 | fool.com.au
Here’s why these 4 ASX shares are soaring today
June 13, 2022 | fool.com.au
Why these 4 ASX shares have sunk lower today
June 13, 2022 | finance.yahoo.com
Bionomics Investor Webinar
June 10, 2022 | finance.yahoo.com
Bionomics Limited (BNO.AX)
May 16, 2022 | finance.yahoo.com
Bionomics Limited to Participate in Upcoming Investor Conferences
May 11, 2022 | finance.yahoo.com
Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
February 23, 2022 | finance.yahoo.com
Bionomics' Half-Year Report
January 14, 2022 | benzinga.com
Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to...
See More Headlines

Company Calendar

Last Earnings
2/15/2019
Today
5/20/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:BNO
CUSIP
N/A
CIK
N/A
Web
www.bionomics.com.au
Phone
+61-8-83546100
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-24,910,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-46.14%
Return on Assets
-20.98%

Debt

Debt-to-Equity Ratio
1.29
Current Ratio
9.05
Quick Ratio
12.02

Sales & Book Value

Annual Sales
$6.02 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
2.69
Book Value
A$0.03 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,470,000,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
2.13

Key Executives

  • Mr. Adrian Hinton BEC (Age 70)
    F.C.A., Financial Controller
    Comp: $323.78k
  • Dr. Spyridon Papapetropoulos M.D. (Age 50)
    Ph.D., CEO, Pres & Director
  • Mr. Timothy M. Cunningham CPA (Age 60)
    CPA, M.B.A., Chief Financial Officer
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
  • Dr. Julie Kerner Ph.D.
    Sr. VP of Bus. Operations
  • Dr. Atul R. Mahableshwarkar DFAPA
    M.D., Acting Chief Medical Officer
  • Ms. Suzanne Irwin B.Com.
    FCIS, Company Sec.

Key Competitors

View All Competitors

BNO Stock Analysis - Frequently Asked Questions

How were Bionomics' earnings last quarter?

Bionomics Limited (ASX:BNO) announced its quarterly earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Bionomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bionomics investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

This page (ASX:BNO) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Does this make you sick?
Allegiance Gold
Dems have chosen Biden replacement?
Paradigm Press
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
This Could be Your “Big Money” AI Moment
InvestorPlace
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest